Drugs / CBP501
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03113188 | Oct 2017 → Feb 2021 | cancer | CanBas Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00551512 | Nov 2006 → May 2009 | cancer | CanBas Co. Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00700336 | May 2008 → Jul 2012 | malignant pleural mesothelioma | CanBas Co. Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04953962 | Dec 2021 → Apr 2023 | pancreatic exocrine neoplasm | CanBas Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00942825 | Apr 2009 → Jul 2013 | non-small cell lung carcinoma | CanBas Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBP501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00942825 ↗ |
| Modality | Peptide | “CBP501 peptide acetate salt (peptide base units)” NCT00700336 ↗ |
| Route | Intravenous | “CBP501 is given IV on Day 1 of each cycle (every 21 days).” NCT00551512 ↗ |